Clinical implications for substandard, nonproprietary medicines in multiple sclerosis: focus on fingolimod
Gestores bibliográficos
Compartir
item.contributor.advisor
ORCID:
Journal Title
Journal ISSN
Volume Title
Publisher
Dove Press Limited
item.page.isbn
item.page.issn
item.page.issne
item.page.doiurl
item.page.extent
9
item.page.accessRights
item.page.other
item.page.references
Abstract
Both proprietary and nonproprietary medicines are expected to undergo rigorous preapproval testing and both should meet stringent health authority regulatory requirements related to quality to obtain ...
Description
item.page.coverage.spatial
item.page.sponsorship
Citation
Correale J, Chiquete E, Boyko A, Beran RG, Strauch JB, Milojevic S, Frider N. Clinical implications for substandard, nonproprietary medicines in multiple sclerosis: focus on fingolimod. Drug Des Devel Ther. 2016 Jun 30;10:2109-17
Keywords
item.page.dc.rights
item.page.dc.rights.url
Estadísticas de uso
1 0,8 0,5 0,3 0
Agosto 2025Septiembre 2025Octubre 2025Noviembre 2025Diciembre 2025Enero 2026Febrero 2026